| MCD |
Report |
Adjusted EPS (Q2'26) |
BEAT |
pred ~$3.40 vs. cons $3.32 |
MEDIUM |
| MCD |
Report |
Global comparable sales (Q2'26) |
IN-LINE |
pred ~+1.5% vs. cons +1.4% |
MEDIUM |
| MCD |
Report |
U.S. comparable sales (Q2'26) |
IN-LINE |
pred ~+0.8% vs. cons +0.95% |
LOW |
| MCD |
Guide |
FY2026 adjusted operating margin guide |
UNCHANGED |
guide ~46% vs. cons ~46% (FY2026) |
MEDIUM |
| MCD |
Guide |
Q2 U.S. company-operated (McOpCo) margin |
LOWER |
guide ~13% vs. cons ~14.5% (Q2'26 U.S. McOpCo) |
MEDIUM |
| MCD |
Guide |
2H2026 U.S. comp / consumer tone |
LOWER |
guide ~flat-to-+1% vs. cons ~+2% (2H2026) |
MEDIUM |
| MCD |
Guide |
FY2026 FX tailwind to EPS |
BETTER |
guide ~+$0.25 vs. cons ~+$0.15 (FY2026 EPS) |
LOW |
| MCD |
Guide |
Refranchising / McOpCo fix detail |
UNKNOWN |
guide deferred to Sept 23 vs. cons ~0 change now (Investor Day) |
MEDIUM |
| MCD |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| MCD |
Return |
5-day cumulative residual |
+0.4% (FADE) |
EPS beat on FX/buybacks plus post-cyclospora stabilization drives a relief bounce off a washed-out, pre-guided-down setup (stock ~-22% off Feb high). But the beat is low-quality: U.S. comps soft, McOpCo margins pressured by beef/labor, and a cautious 2H consumer tone forces out-period estimate cuts. Out-period math (implicit H2 downgrades) drags the initial pop back toward flat; downside cushioned by extreme washout and the Sept 23 Investor Day forward catalyst, so it fades rather than fully reverses. |
LOW |